Device Trial Radar · NCT04494035
AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System
Last checked: Nov 20, 2026Latest source record: Sep 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
7
Actual
Start
Jan 14, 2020
Primary completion
Oct 23, 2020
Study completion Oct 23, 2020
Sponsor
- Lead sponsor
- Medtronic EndovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Jul 31, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, single-arm, non-blinded study, intending to treat and collect and evaluate data in up to ten (10) human subjects who are currently being treated with hemodialysis and who present with acute thrombosis in their arteriovenous (AV) grafts, treated with the CAPERE® Thrombectomy System.
Conditions
- Arteriovenous Graft Thrombosis
Interventions
CAPERE Thrombectomy SystemDevice
Arteriovenous graft thrombectomy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Endpoint (Effectiveness)Time frame: Intraoperative
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Health Network Toronto General
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.